- Home
- NTIP vs LTRN Comparison
NTIP vs LTRN Comparison
Compare NTIP & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- LTRN
- Stock Information
- Founded
- NTIP 1990
- LTRN 2013
- Country
- NTIP United States
- LTRN United States
- Employees
- NTIP N/A
- LTRN N/A
- Industry
- NTIP Multi-Sector Companies
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- LTRN Health Care
- Exchange
- NTIP Nasdaq
- LTRN Nasdaq
- Market Cap
- NTIP 32.9M
- LTRN 46.7M
- IPO Year
- NTIP 1998
- LTRN 2020
- Fundamental
- Price
- NTIP $1.36
- LTRN $3.74
- Analyst Decision
- NTIP
- LTRN Hold
- Analyst Count
- NTIP 0
- LTRN 1
- Target Price
- NTIP N/A
- LTRN N/A
- AVG Volume (30 Days)
- NTIP 18.4K
- LTRN 47.1K
- Earning Date
- NTIP 02-28-2025
- LTRN 05-08-2025
- Dividend Yield
- NTIP 7.30%
- LTRN N/A
- EPS Growth
- NTIP N/A
- LTRN N/A
- EPS
- NTIP N/A
- LTRN N/A
- Revenue
- NTIP $100,000.00
- LTRN N/A
- Revenue This Year
- NTIP N/A
- LTRN N/A
- Revenue Next Year
- NTIP N/A
- LTRN N/A
- P/E Ratio
- NTIP N/A
- LTRN N/A
- Revenue Growth
- NTIP N/A
- LTRN N/A
- 52 Week Low
- NTIP $1.22
- LTRN $2.79
- 52 Week High
- NTIP $2.15
- LTRN $11.99
- Technical
- Relative Strength Index (RSI)
- NTIP 47.21
- LTRN 42.37
- Support Level
- NTIP $1.33
- LTRN $3.40
- Resistance Level
- NTIP $1.38
- LTRN $4.00
- Average True Range (ATR)
- NTIP 0.03
- LTRN 0.33
- MACD
- NTIP -0.00
- LTRN -0.04
- Stochastic Oscillator
- NTIP 37.50
- LTRN 32.11
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.